prikaz prve stranice dokumenta Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic
Access restricted to all Croatian higher education institution's students and staff
Scientific paper - Review paper
Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic
Rheumatology International, 44 (2024), 5; 749-755. https://doi.org/10.1007/s00296-023-05531-y
Zekić, Tatjana; Belančić, Andrej

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Zekić, T. & Belančić, A. (2024). Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic. Rheumatology International, 44. (5), 749-755. doi: 10.1007/s00296-023-05531-y

Zekić, Tatjana and Andrej Belančić. "Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic." Rheumatology International, vol. 44, no. 5, 2024, pp. 749-755. https://doi.org/10.1007/s00296-023-05531-y

Zekić, Tatjana and Andrej Belančić. "Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic." Rheumatology International 44, no. 5 (2024): 749-755. https://doi.org/10.1007/s00296-023-05531-y

Zekić, T. and Belančić, A. (2024) 'Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic', Rheumatology International, 44(5), pp. 749-755. doi: 10.1007/s00296-023-05531-y

Zekić T, Belančić A. Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic. Rheumatology International [Internet]. 2024 February 23 [cited 2024 December 30];44(5):749-755. doi: 10.1007/s00296-023-05531-y

T. Zekić and A. Belančić, "Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic", Rheumatology International, vol. 44, no. 5, pp. 749-755, February 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:102616. [Accessed: 30 December 2024]

Metadata
Title (english)Antiphospholipid syndrome, thrombosis, and vaccination in the COVID-19 pandemic
AuthorTatjana Zekić
AuthorAndrej Belančić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Pharmacology)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Thrombosis is one of the many signs of antiphospholipid syndrome (APS) and COVID- 19 infection. Although the mechanisms contributing to thrombosis in APS and COVID- 19 are relatively similar, this remains an open subject. Even now (when the COVID-19 pandemic has subsided), there is no conclusive solution to APS and COVID-19 cooccurrence. The presence of newly generated antiphospholipid antibodies (aPLs) in COVID-19 infection may or may not be connected to the diagnosis of APS. The prevalence of aPLs is substantial in severe COVID-19 but not related to thrombosis or a worse outcome. Adequate monitoring of antibody positivity over time is recommended for APL diagnosis. On the other hand, thrombosis and thrombocytopenia can rarely occur with vaccination with mRNA vaccines. Some studies have shown that COVID-19 immunization is well tolerated among APS patients who are triple-positive for aPL, which may comfort patients and referring physicians and lessen hesitation in unvaccinated APS/aPL-positive patients. In this narrative review we will give an overview of the interaction between aPL-APS-COVID-19- thrombosis and related diagnostic insights learned during the pandemic.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleRheumatology International
Numberingvol. 44, no. 5, pp. 749-755
e-ISSN1437-160X
DOIhttps://doi.org/10.1007/s00296-023-05531-y
URN:NBNurn:nbn:hr:184:102616
Publication2024-02-23
Document URLhttps://link.springer.com/10.1007/s00296-023-05531-y
Type of resourceText
Access conditionsRestricted access
Terms of useLicence In copyright icon
Created on2024-12-09 12:52:44